2. Academic Validation
  3. Human umbilical cord-derived mesenchymal stromal cells alleviate liver cirrhosis through the Hippo/YAP/Id1 pathway and macrophage-dependent mechanism

Human umbilical cord-derived mesenchymal stromal cells alleviate liver cirrhosis through the Hippo/YAP/Id1 pathway and macrophage-dependent mechanism

  • Int Immunopharmacol. 2023 Jul 24;123:110456. doi: 10.1016/j.intimp.2023.110456.
Lichao Yao 1,  Xue Hu 1,  Mengqin Yuan 1,  Pingji Liu 1,  Qiuling Zhang 1,  Zheng Wang 1,  Ping Chen 1,  Zhiyu Xiong 1,  Lun Wu 2,  Kai Dai 3,  Yingan Jiang 4
Affiliations

Affiliations

  • 1 Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, People's Republic of China.
  • 2 Experiment Center of Medicine, Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan 442008, People's Republic of China. Electronic address: [email protected].
  • 3 Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, People's Republic of China. Electronic address: [email protected].
  • 4 Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, People's Republic of China. Electronic address: [email protected].
PMID: 37494836 DOI: 10.1016/j.intimp.2023.110456
Abstract

Background: Few effective anti-fibrotic therapies are currently available for liver cirrhosis. Mesenchymal stromal cells (MSCs) ameliorate liver fibrosis and contribute to liver regeneration after cirrhosis, attracting much attention as a potential therapeutic strategy for the disease. However, the underlying molecular mechanism of their therapeutic effect is still unclear. Here, we investigated the effect of human umbilical cord-derived mesenchymal stromal cells (hUC-MSCs) in treating liver cirrhosis and their underlying mechanisms.

Methods: We used carbon tetrachloride (CCl4)-induced mice as liver cirrhosis models and treated them with hUC-MSCs via tail vein injection. We assessed the changes in liver function, inflammation, and fibrosis by histopathology and serum biochemistry and explored the mechanism of hUC-MSCs by RNA sequencing (RNA-seq) using liver tissues. In addition, we investigated the effects of hUC-MSCs on hepatic stellate cells (HSC) and macrophages by in vitro co-culture experiments.

Results: We found that hUC-MSCs considerably improved liver function and attenuated liver inflammation and fibrosis in CCl4-injured mice. We also showed that these cells exerted therapeutic effects by regulating the Hippo/YAP/Id1 axis in vivo. Our in vitro experiments demonstrated that hUC-MSCs inhibit HSC activation by regulating the Hippo/YAP signaling pathway and targeting Id1. Moreover, hUC-MSCs also alleviated liver inflammation by promoting the transformation of macrophages to an anti-inflammatory phenotype.

Conclusions: Our study reveals that hUC-MSCs relieve liver cirrhosis in mice through the Hippo/YAP/Id1 pathway and macrophage-dependent mechanisms, providing a theoretical basis for the future use of these cells as a potential therapeutic strategy for patients with liver cirrhosis.

Keywords

Hepatic stellate cells; Hippo/YAP; Human umbilical cord-derived mesenchymal stromal cells; Liver cirrhosis; Macrophages.

Figures
Products
Inhibitors & Agonists
Other Products